Friday, October 20, 2017 8:04:52 PM
"Favorable PISCES Data Could Unlock ~10K Stage III/IV Melanoma Anti-PD-1 Failure Patients (US Only)"
Punit threw out the multi-billion dollar comment when he went on to state where the value for immunopulse-il12 combo therapy might be if you multiplied the number of other indications they could go after.
Punit also has compared t-vec to Oncosec therapy in terms of a buyout value. Biovet (t-vec therapy) was bought out buy Amgen for around $1 billion I believe.
I received an Oncosec report from Maxim a few months ago stating that they believed that with an FDA approval for PISCES, Oncosec could turn profitable in the year 2021 without an accelerated approval (their conservative estimate-and $5 target). They estimate a profit of $45.7 million first year, $92.3 million 2nd year, $144 million 3rd year, $220 million 4th year in melanoma. So with accelerated approval that timeframe could move up to 2019 as the year they turn a profit.
Maxim also put out numbers for Merkel Cell and TNBC if Oncosec were approved for those indications later by 2021-2023. TNBC would be close to the melanoma numbers, but a little under. TNBC would bring in about $40 million first year and $70 million second year. Merkel Cell lower numbers at $25 million first year, $53 million second year, $69 million 3rd year.
So multiple indications get you to the billion dollar mark in time if you have a growing cancer population as has been predicted (sadly) in the future 10 to 20 years.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM